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NK cells preferentially recognize and kill cells that lack
expression of MHC class I (1). While inhibitory receptors
expressing immunoreceptor tyrosine-based inhibition mo-
tifs prevent NK cells from harming tissues expressing nor-
mal levels of classical or nonclassical MHC class I (for a re-
view, see reference 2), what turns on NK cells? Recent
reports (3, 4), including Smith et al. in this issue (4), are be-
ginning to unfold the receptors and signaling pathways in-
volved in positive activation of NK cells.
Unlike T cells or B cells, which recognize antigen using
clonally restricted receptors generated by gene rearrange-
ment, NK cells appear to use a variety of different, nonre-
arranging receptors to initiate cytolytic activity and cyto-
kine production (for a review, see reference 5). Many of
these activating receptors are not restricted to NK cells;
most are also present on T cells, and these serve as costimu-
latory or adhesion receptors in both cell types. Like the
ability of antibodies against CD3 or the T cell antigen re-
ceptor to trigger killing or cytokine production by cyto-
toxic T cells, a productive strategy to search for activating
NK cell receptors has involved screening for mAbs that ini-
tiate NK cell killing of Fc receptor–bearing tumor cell
lines. Using this approach, several membrane receptors
have been implicated in NK cell activation, including CD2
(6), CD16 (7), Ly6 (8), CD44 (9, 10), CD69 (11), NKR-
P1 (8, 12), 2B4 (13–15), DNAM-1 (16), NKG2D (17),
CD94/NKG2C (18), NKp44 (19), NKp46 (20), and
NKp30 (3). The ligands for some of these receptors are
known (e.g., CD2 for CD58 [21], 2B4 for CD48 [22],
CD16 for IgG [23, 24], NKG2D for MICA [17], and
CD94/NKG2C for HLA-E [25]). Expression of the ligands
on target cells can initiate NK cell lysis or cytokine produc-
tion, provided the NK cells are not turned off by inhibitory
NK receptors recognizing class I molecules on the targets.
Although several different activating NK cell receptors
have been identified, many share a common adaptor mole-
cule or signaling pathway. Recently, Pende et al. (3) re-
ported that NKp30 lacks known signaling motifs in its cy-
toplasmic domain, but noncovalently associates with CD3
 
z
 
to provide for cellular activation. CD16 also associates with
CD3
 
z
 
 (26), or the structurally similar Fc
 
e
 
RI
 
g
 
 chain (27,
28), and this receptor complex mediates antibody-depen-
dent cellular cytotoxicity. NKp46 (29) and mouse NKR-
P1 (30) are other NK cell receptors linked to CD3
 
z
 
 or
Fc
 
e
 
RI
 
g
 
, respectively. Although not physically associated,
CD3
 
z
 
 has been implicated in CD2-mediated activation of
NK cells (31). NK cells express both CD3
 
z
 
 and Fc
 
e
 
RI
 
g
 
,
and these adaptor molecules form disulfide-bonded ho-
modimers, as well as heterodimers with each other (28).
CD3
 
z
 
 and Fc
 
e
 
RI
 
g
 
 have immunoreceptor tyrosine-based
activation motifs (ITAMs) in their cytoplasmic domains
that upon phosphorylation caused by receptor ligation re-
cruit the cytoplasmic tyrosine kinases Syk and ZAP70
(both of which are expressed in NK cells; for a review, see
reference 32). Ligands for NKp30, NKp46, and NKR-P1
have not been identified; however, there are suggestions
that these receptors are involved in NK cell recognition of
certain tumors (3, 19, 33).
Other activating NK cell receptors signal by association
with another ITAM-containing adaptor protein, DAP12.
Like CD3
 
z
 
, DAP12 has a very short extracellular domain
(of 
 
z
 
14 amino acids) and is expressed as a disulfide-bonded
homodimer on the surface of NK cells, myeloid cells, and a
subset of T cells (34, 35). Whereas CD3
 
z
 
 has three ITAMs,
DAP12 and Fc
 
e
 
RI
 
g
 
 each have a single ITAM. DAP12 as-
sociates with the activating isoforms of the human killer
cell Ig-like receptors (KIRs) (34), mouse Ly49D and
Ly49H (36, 37), the CD94/NKG2C receptor (38), and
NKp44 (39). In this issue, Smith et al. (4) describe an mAb
against Ly49H and demonstrate that cross-linking this re-
ceptor results in the activation of a subset of mouse NK
cells. Known ligands of these DAP12-associated receptors
include HLA-C for KIR, HLA-E for CD94/NKG2C, and
H-2D
 
d
 
 for Ly49D (to date, the ligand for Ly49H has not
been identified). As with CD3
 
z
 
 or Fc
 
e
 
RI
 
g
 
, ligation of
these DAP12-associated receptors results in tyrosine phos-
phorylation of the ITAM of DAP12 and recruitment of
Syk or ZAP70 (34, 40), thereby initiating cytolytic activity
and cytokine production. DAP12, CD3
 
z
 
, and Fc
 
e
 
RI
 
g
 
 all
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possess an acidic amino acid (aspartic acid) in their trans-
membrane domains that provides for their association with
charged amino acids in the transmembrane domains of
the ligand-binding receptor subunits. While CD3
 
z
 
 and
Fc
 
e
 
RI
 
g 
 
may be interchangeable in their association with
certain partners, DAP12 interacts with completely distinct
glycoproteins, indicating exquisite specificity in these mul-
tisubunit receptor complexes.
NK cell development and cytolytic function are intact in
mice or humans with disrupted ZAP70 (41, 42) or Syk (43)
genes, suggesting the existence of receptors using other sig-
naling pathways. Activating NK cell receptors not linked to
ITAM-containing adaptor proteins have been identified.
The activating NK cell receptor 2B4 (13, 14, 44) uses a sig-
naling pathway involving the cytoplasmic tyrosine phos-
phatase SHP-2 and the Src homology 2 (SH2)-containing
intracellular adaptor protein SAP (15). SAP, identified by
its association with the T cell costimulatory molecule
SLAM (45), likely serves a common role for several recep-
tors in NK and T cells. NKG2D, an activating receptor on
T and NK cells for the nonclassical MICA and MICB anti-
gens (17), uses the DAP10 adaptor protein for signal trans-
duction (46). DAP10 is a membrane-anchored, disulfide-
linked homodimer with an acidic amino acid (aspartic acid)
in the transmembrane that permits association with a basic
amino acid (arginine) in the transmembrane of NKG2D
(46). Phosphorylation of the tyrosine residue in the YxxM
motif in the DAP10 cytoplasmic domain recruits the p85
subunit of phosphatidylinositol 3-kinase (PI3-kinase) (46).
Inhibitors of PI3-kinase prevent NKG2D-mediated NK
cell cytotoxicity and cytokine production, implicating this
signaling pathway in DAP10-induced activation. Expres-
sion of DAP10 in myeloid cells, which lack NKG2D, pre-
dicts the existence of other receptors that will use DAP10
for signal transduction (46).
Although many receptors are now being implicated in
NK cell activation, it is uncertain whether any individual
receptor alone will be sufficient to initiate effector func-
tion. Rather, additive or synergistic interactions between
multiple receptors may be necessary to stimulate cytotoxic-
ity and cytokine production. Experimental findings support
the latter. In the recent studies of Pende et al. (3), the mAb
against NKp30 alone only marginally blocked NK cell kill-
ing of several tumors. However, more dramatic effects
were observed when blocking antibodies against several
NK cell receptors and adhesion molecules were used in
combination. Thus, the emerging concept is that NK cell
function is determined by the integration of signals from
several activating receptors that are regulated by the inhibi-
tory receptors for MHC class I, based on the density and
array of ligands and class I molecules expressed by the anti-
gen-presenting cell. Infection and inflammation are often
accompanied by the release of local cytokines (e.g., IL-15,
TNF-
 
a
 
, type I IFNs, chemokines). These cytokines may
serve not only to activate NK cells, but also to upregulate
ligands (e.g., the intercellular adhesion molecules [ICAMs],
CD48, CD58) for adhesion or costimulatory receptors that
are present on NK cells. In this environment, rich in stim-
ulatory cytokines and ligands for activating receptors, NK
cells may provide a critical bridge between the innate and
adaptive immune systems.
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